eligibility_summary
Adults ≥18 with recurrent/metastatic ovarian, endometrial, or other solid tumors, measurable non‑brain/bone lesion, available tumor tissue, ECOG 0–1, life ≥12 wks. Exclude: recent B7‑H4/other anti‑cancer therapy, radiation or major surgery, QT‑prolongers/CYP interactors, ≥Gr2 toxicities, effusions, unstable brain mets, major organ/cardiac dysfunction, uncontrolled DM/HTN, bleeding/thrombosis, infections/immunodef, lung/neuropsych disease, pregnancy, live vaccine, severe allergy, noncompliance.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: HS-20089, an investigational antibody-drug conjugate (humanized IgG1) that targets B7-H4 (VTCN1/B7x) on tumor cells. Mechanism: After binding B7-H4, the ADC is internalized, a protease-cleavable linker releases a topoisomerase I inhibitor payload (DAR ~6), causing DNA damage/replication stress and apoptosis in dividing tumor cells. Targets: B7-H4–expressing malignant epithelial cells in ovarian, fallopian tube, primary peritoneal, and endometrial cancers, pathways include the B7-H4 immune checkpoint (as the tumor-associated antigen for selective delivery) and the DNA replication/repair pathway via topoisomerase I inhibition.